View More Recent Stories
-
Savara (SVRA) PT Raised to $10 at H.C. Wainwright
-
Savara (SVRA) PT Raised to $10 at JMP Securities
-
Savara (SVRA) PT Raised to $15 at Oppenheimer
-
Savara (SVRA) Reports Molgramostim Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2
-
Piper Sandler Reiterates Overweight Rating on Savara (SVRA)
